*PLEASE NOTE: ALL TIMINGS LISTED AS FOLLOWS: EST | PST*
9.30 | 6.30 – Virtual Coffee Networking Morning
10.00 | 7.00 – Morning Chair’s Opening Remarks
Liquid Biopsies & Broadening Industry Applications
10.10 | 7.10 – Liquid Biopsy Assay Supporting Drug Development: Faster & Focused Enrollment
Synopsis
- Liquid biopsies to support identification of patient responders, speedy enrollment and ensure safety and efficacy in target population
- What the successful and synchronized launch of both drug-Dx to market means for the future successes and applications of a therapeutic
- Realizing the prognostic and predictive value of treatments via associated assays
10.40 | 7.40 – Expertise Panelist Discussion: The Additive Role of CTCs & ctDNA in Your Clinical Development Strategy
Synopsis
- Complementing your biomarker evaluation with CTCs
- Comprehensive cancer profiling: CTCs and ctDNA
- Banking the remnant plasma and slides for future analysis
11.10 | 8.10 – Novel Biomarkers on the Horizon: Epigenetics to Detect Cancer Early
Synopsis
- Discovery and development of new promising new biomarkers for screening and surveillance
- Opportunities for future targeted therapy development
- Early-detection only using ncRNAs and DNA methylation
11.40 | 8.40 – Key Lessons From the Incremental Use of Liquid Biopsy Testing in the Management & Treatment of Cancer Patients
Synopsis
- Liquid biopsy applications currently available for clinical care: the impact on our ability to deliver precision medicine
- Clinical utility of liquid biopsy in overcoming pandemic-related barriers to cancer care
- Liquid biopsy support for pharmaceutical clinical trials: the tangible benefits and intangible opportunities
12.10 | 9.10 – Speed Networking
12.35 | 9.35 – Event Partner Networking Break
13.00 | 11.00 – Practical Applications of ctDNA Testing for Residual Disease & Recurrence
Synopsis
• RaDaR assay has industry leading sensitivity – why is this important?
• Using residual disease and recurrence opens new options for clinical
trial design
• Data from a recent NSCLC clinical trial
13.30 | 10.30 – Longitudinal Monitoring of Melanoma Patients Receiving Checkpoint Inhibitor Immunotherapies Using Cell Free MiRNA
Synopsis
- Profiling of cf miRNA by NGS to identify signatures in metastatic melanoma patients of stage 3 and 4
- Identification of cf miRNA signatures that correlate to checkpoint inhibitor immunotherapy responses
- Early detection of progression disease failure during immunotherapy failure
14.00 | 11.00 – Utility of Circulating Tumor DNA in Informing the Patient Journey
Synopsis
- When ctDNA can inform disease and treatment decisions
- What it will take for ctDNA to inform the patient journey
- Why ctDNA will not be the only option for cancer diagnostics
14.30 | 11.30 – Interactive Roundtable: New Thinking for Liquid Biopsy Approaches
With two roundtables running in parallel, pick which conversation you would like to join and contribute to alongside your peers.
Which Indications Can Learn From Successes in Oncology?
• Liquid biopsy application in oncology is seeing successes in over 10 tumor types and holds great promise for the future, can other disease areas learn from these approaches?
• Adapting technologies for detection of circulating biomarkers of similar size in indications where existing diagnosis methods are inadequate /invasive
• What does the pandemic, and response from liquid biopsy leaders, tell us about the potential clinical utility of these technologies across today’s healthcare continuum
Jean-Francois Martini, Senior Director, Translational Oncology Lead, Global Product Development Pfizer
15.10 | 12.10 – Panel Discussion: Starting With the End in Mind, Industry Collaboration for Industry Standards
Synopsis
- How can the industry better work together to unpick and target tumor heterogeneity?
- What can we learn from past successful Drug-Dx collaborations?
- Collaborations and partnering to support regulatory submission pathways
15.50 | 12.50 – Extracellular Vesicles as Emerging Liquid Biopsy Biomarkers
Synopsis
- Extracellular vesicles (EVs) are a group of heterogeneous membranebound vesicles that include exosomes, microvesicles and apoptotic bodies, which are actively secreted by almost all cell types into extracellular spaces
- EVs contain cargo from their originating cells, including DNA, RNA and protein, which is protected by the lipid bilayer from exogenous degradation while in circulation
- Emerging evidence has shown the role of EVs and their molecular cargo in promoting pathological processes in various diseases such as cancer and neurodegenerative diseases, with many studies linking specific EV cargo to disease progression and outlook
16.20 | 13.20 – Chair’s Closing Remarks: What’s Next For Liquid Biopsy in Precision Oncology
Synopsis
- What new opportunities are there for liquid biopsies to further precision therapy approaches in oncology
- What does clinical evidence show us in terms of liquid biopsy replacing the ‘gold standard’ become a reality in some instances – (Drawing on case study examples)
- Reflecting on the core challenges industry needs to solve